Important Update on Listing Status and Strategic Direction
- None.
- None.
Insights
The transition of Nemaura Medical from The Nasdaq Capital Market to the OTC Markets is a significant strategic shift that warrants a close examination of its implications. The reduced compliance costs and increased operational flexibility on the OTC Markets can be beneficial for small-cap companies like Nemaura Medical. However, the move also typically results in reduced visibility and liquidity compared to Nasdaq, which may affect investor perception and the ability to attract institutional investors. Furthermore, the decision to avoid a 90% dilution by not maintaining the Nasdaq listing suggests that the company is prioritizing existing shareholder value over potential capital from a broader market.
Strategic partnerships are often crucial for growth in the medical technology sector. Nemaura Medical's focus on securing partnerships to fund innovation and expand market presence could be a pivotal factor in its long-term success. These partnerships could enable the company to leverage external expertise and resources, which might be particularly important given the delisting context, as the company will need to find alternative ways to sustain its growth trajectory and market competitiveness.
Delisting from a major exchange like Nasdaq is a financial maneuver that impacts investor confidence and stock liquidity. For Nemaura Medical, this decision appears to be a trade-off between immediate financial pressures and long-term strategic positioning. The avoidance of a 90% dilution indicates that the company is keen on protecting shareholder value, but it also raises questions about the company's financial health and future funding capabilities. Investors should closely monitor the company's financial disclosures in subsequent annual and quarterly reports for indicators of financial stability and the effectiveness of the strategic partnerships mentioned.
It is also essential to consider the potential impact on the company's cost of capital. While moving to the OTC Markets may reduce certain regulatory costs, it could also increase the cost of capital due to higher perceived risks by investors. This could affect the company's ability to invest in research and development, which is critical in the medical technology industry.
Nemaura Medical's core product, a non-invasive glucose sensor, operates within a highly competitive and innovation-driven market. The company's ability to maintain its relevance and growth in the digital healthcare space hinges on continuous innovation and market adoption. The decision to delist may allow Nemaura Medical to allocate more resources towards product development and strategic partnerships, which could enhance its competitive edge. However, the move also suggests potential challenges in funding and market performance that could impede these efforts.
Investors should evaluate the company's research and development pipeline and the strategic partnerships' potential to bring products to market more efficiently. The success of these partnerships will likely be a determining factor in the company's ability to maintain a competitive position within the industry, especially given the reduced market exposure from the OTC listing.
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction.
Background:
After thorough analysis, Nemaura Medical’s Board of Directors and management team have made the strategic decision to accept Nasdaq’s determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our control that have led to a significant attrition of the share price. In light of these circumstances, maintaining our Nasdaq listing would necessitate a substantial dilution of approximately
Benefits of the OTC Markets:
The transition to the OTC Markets will provide operational flexibility, reduced compliance costs, and the ability to focus on long-term growth without the immediate pressures associated with maintaining a Nasdaq listing.
Strategic Partnerships:
Committed to creating shareholder value, we are actively pursuing strategic partnerships critical to driving Nemaura Medical's growth. We believe these partnerships will play a key role in securing the necessary funding to propel innovation, expand market presence, and enhance our overall competitiveness.
Shareholder Role in Our Future Success:
We understand that this decision may raise questions and concerns. We want to assure shareholders that we remain committed to open and transparent communication. We value shareholder trust and support and are dedicated to keeping shareholders informed throughout this transition.
As we navigate this new phase, regular updates on our progress, strategic partnerships, and any material developments impacting shareholders will be provided. Additionally, in the near-term, we will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC. Please feel free to reach out to our Investor Relations team via email (IR@nemauramedical.com) with any questions or if further clarification is needed.
Thank you for your continued trust and confidence in Nemaura Medical. Together, we look forward to shaping a successful future.
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura Medical has submitted a proposal for a Modular PMA (Premarket Approval Application) application for sugarBEAT® to the U.S. FDA, for its generation II, 24-hour sensor. proBEAT™ is a non-regulated version of sugarBEAT which combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program.
Additionally, Nemaura Medical launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura Medical believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking Statements:
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the “FDA”) reserves the right to re-evaluate its decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K, each as may be amended from time to time. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations Contact:
FAQ
Why is Nemaura Medical Inc. (NMRD) moving from Nasdaq to OTC Markets?
What are the benefits of the transition to the OTC Markets for Nemaura Medical Inc. (NMRD)?
How will strategic partnerships impact Nemaura Medical Inc. (NMRD)'s growth?
How will Nemaura Medical Inc. (NMRD) communicate with shareholders during the transition?
What reports will Nemaura Medical Inc. (NMRD) continue to file with the SEC after the transition?
How can shareholders contact Nemaura Medical Inc. (NMRD) for further information?
What is the ticker symbol for Nemaura Medical Inc.?
